Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies

Autor: D.J. Khalaf, I.M. Aragón, M. Annala, R. Lozano, S. Taavitsainen, D. Lorente, D.L. Finch, N. Romero-Laorden, J. Vergidis, Y. Cendón, C. Oja, M.I. Pacheco, M. Zulfiqar, M.E. Gleave, A.W. Wyatt, D. Olmos, K.N. Chi, E. Castro, E. Almagro, J.Á. Arranz, E.G. Billalabeitia, P. Borrega, J.A. Contreras, M. Domenech, R. Escribano, E. Fernández-Parra, E. Gallardo, I. García-Carbonero, R. García, J. Garde, A. González del Alba, B. González, A. Hernández, S. Hernando, P. Jiménez, N. Laínez, R. Luque, E. Martínez, A. Medina, M.J. Méndez-Vidal, A. Montesa, R. Morales, null Olmos David, J.L. Pérez-Gracia, B. Pérez-Valderrama, Á. Pinto, J. Piulats, J. Puente, R. Querol, A. Rodríguez-Vida, M.I. Sáez, S. Vázquez, E. Vélez, J.C. Villa-Guzmán, R. Villatoro, C. Zambrana

Background A common polymorphism (1245A>C) in the HSD3B1 gene is associated with increased de novo synthesis of androgens and worse outcomes in men treated with androgen-deprivation therapy for metastatic castration-sensitive prostate cancer. The obj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9314d3782c3e9be3bf57d8cc86f7fa53
https://hdl.handle.net/10668/15803

SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)

Autor: B. Pérez-Valderrama, Sergio Vázquez, José Muñoz-Langa, Nuria Lainez, A. González del Alba, G. de Velasco, Cristina Caballero, Rafael Morales-Barrera, Pablo Maroto, Laura Basterretxea

Publikováno v: CLINICAL & TRANSLATIONAL ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
Clinical & Translational Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Scientia
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya

Càncer de bufeta; Cistectomia; Quimioteràpia Cáncer de vejiga; Cistectomía; Quimioterapia Bladder cancer; Cystectomy; Chemotherapy The goal of this article is to provide recommendations about the management of muscle-invasive (MIBC) and metastati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14b54a5eeaaf4309e01f3ef95a08c17d
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13065

Correction to: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

Autor: Begoña Mellado, Miguel Angel Climent, Javier Cassinello, David Olmos, M. Lázaro, Josep M. Piulats, Joan Carles, A. Sánchez, B. Pérez-Valderrama, J. A. Arranz

The original article shows two mistakes, which are listed here.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc863bb82a7507fb8723726148b485a8
https://hdl.handle.net/10668/11973

Correlation between time to PSA progression (TTPP), radiographic progression-free survival (rPFS) and overall survival (OS) in first-line abiraterone/enzalutamide (Abi/Enza) and docetaxel (Doc) treated patients in a prospective cohort study

Autor: A. Montesa, Fernando López-Campos, Javier Puente, M Isabel Sáez, Josep M. Piulats, Casilda Llacer Perez, M.J. Méndez-Vidal, David Olmos, Elena Almagro, Rafael Morales-Barrera, Nuria Romero-Laorden, Nuria Lainez, Elena Castro, David Lorente, Alejo Rodriguez Vida, Rebeca Lozano, Susana Hernando Polo, Amaia Hernandez, B. Pérez-Valderrama, Eva Fernandez

Publikováno v: Journal of Clinical Oncology. 37:267-267

267 Background: Abiraterone, enzalutamide and docetaxel represent first-line (1L) treatment options in mCRPC. A significant correlation between rPFS and OS has been reported for patients treated with 1L abi and enza in mCRPC. It is however unclear wh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::82cf993e41e74adf4b1c9c35204a719a
https://doi.org/10.1200/jco.2019.37.7_suppl.267